{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:38:48Z","timestamp":1770993528550,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"3-4","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.beha.2014.10.006","type":"journal-article","created":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T18:50:50Z","timestamp":1413312650000},"page":"247-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Will novel agents for ALL finally change the natural history?"],"prefix":"10.1016","volume":"27","author":[{"given":"Dan","family":"Douer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2014.10.006_bib1","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","article-title":"Modern therapy of acute lymphoblastic leukemia","volume":"29","author":"Bassan","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.10.006_bib2","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.bbmt.2010.11.024","article-title":"Interpreting data on transplant selection and outcome in adult acute lymphoblastic leukemia (ALL)","volume":"17","author":"Rowe","year":"2011","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.beha.2014.10.006_bib3","doi-asserted-by":"crossref","first-page":"858","DOI":"10.6004\/jnccn.2012.0089","article-title":"Acute lymphoblastic leukemia","volume":"10","author":"Alvarnas","year":"2012","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.beha.2014.10.006_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0305-7372(78)80009-7","article-title":"The management of adult acute lymphoblastic leukaemia","volume":"5","author":"Woodruff","year":"1978","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.beha.2014.10.006_bib5","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A\u00a0five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811","volume":"85","author":"Larson","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.10.006_bib6","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.10.006_bib7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood.V64.1.267.267","article-title":"Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B","volume":"64","author":"Gottlieb","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.10.006_bib8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.27617","article-title":"Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802","volume":"119","author":"Stock","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2014.10.006_bib9","article-title":"Intensification of induction and consolidation improves only subgroups of adult ALL: analysis of 1200 patients in GMALL study 05\/93","volume":"98","author":"Gokbuget","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.10.006_bib10","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.10.006_bib11","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2002.07.116","article-title":"Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia","volume":"20","author":"Linker","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.10.006_bib12","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1200\/jco.2005.23.16_suppl.6516","article-title":"A\u00a0randomized trial demonstrating the superiority of cytarabine with high-dose mitoxantrone compared to a standard vincristine\/prednisone-based regimen as induction therapy for adult patients with ALL","volume":"23","author":"Weiss","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.10.006_bib13","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2014.10.006_bib14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/10428194.2010.532889","article-title":"Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone\/methotrexate, cytarabine: results from an Australian population","volume":"52","author":"Morris","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2014.10.006_bib15","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.10.006_bib16","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1200\/JCO.2007.13.7265","article-title":"Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96","volume":"26","author":"Ribera","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.10.006_bib17","first-page":"839","volume":"122","author":"Gokbuget","year":"2013","journal-title":"Blood (ASH Annual Meeting)"},{"key":"10.1016\/j.beha.2014.10.006_bib18","first-page":"3903","article-title":"Frontline-treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a peditric regimen is feasible: toxicity results of the prospective US Intergroup Trial C10403 (Alliance)","volume":"122","author":"Advani","year":"2013","journal-title":"Blood (ASH Annual Meeting)"},{"key":"10.1016\/j.beha.2014.10.006_bib19","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1002\/cncr.25319","article-title":"Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen","volume":"116","author":"Thomas","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2014.10.006_bib20","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1200\/JCO.2013.50.2708","article-title":"Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia","volume":"32","author":"Douer","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.10.006_bib21","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.beha.2008.08.004","article-title":"Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?","volume":"21","author":"Douer","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.beha.2014.10.006_bib22","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1200\/JCO.2005.11.411","article-title":"Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia","volume":"23","author":"Pession","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.10.006_bib23","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","article-title":"Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel","volume":"52","author":"Stock","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2014.10.006_bib24","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study","volume":"27","author":"Huguet","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.10.006_bib25","doi-asserted-by":"crossref","first-page":"181a","DOI":"10.1182\/blood.V110.11.587.587","article-title":"A\u00a0multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia","volume":"110","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.10.006_bib26","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2014.10.006_bib27","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","article-title":"Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"24","author":"Jeha","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.10.006_bib28","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B Study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.10.006_bib29","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2012.46.2309","article-title":"High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"31","author":"O'Brien","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.10.006_bib30","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood-2013-01-480822","article-title":"Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group","volume":"122","author":"Salzer","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.10.006_bib31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00043426-200404000-00002","article-title":"Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961","volume":"26","author":"Panosyan","year":"2004","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.beha.2014.10.006_bib32","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1182\/blood-2012-02-410373","article-title":"CARs and cancers: questions and answers","volume":"119","author":"Brentjens","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.10.006_bib33","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.10.006_bib34","first-page":"67","article-title":"T\u00a0cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce significant in\u00a0vivo proliferation, complete responses and long-term persistence without GvHD in children and adults with relapsed, refractory ALL","volume":"122","author":"Grupp","year":"2013","journal-title":"Blood (ASH Annual Meeting)"},{"key":"10.1016\/j.beha.2014.10.006_bib35","first-page":"68","volume":"122","author":"Lee","year":"2013","journal-title":"Blood (ASH Annual Meeting)"},{"key":"10.1016\/j.beha.2014.10.006_bib36","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.beha.2014.10.006_bib37","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.yexcr.2011.03.010","article-title":"Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab","volume":"317","author":"Nagorsen","year":"2011","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.beha.2014.10.006_bib38","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.10.006_bib39","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1200\/jco.2012.30.15_suppl.6500","article-title":"Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed\/refractory B-precursor ALL","volume":"30","author":"Topp","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.10.006_bib40","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.10.006_bib41","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1200\/jco.2014.32.15_suppl.7005","article-title":"Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed\/refractory B-precursor acute lymphoblastic leukemia (r\/r ALL)","volume":"32","author":"Topp","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.10.006_bib42","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood.V116.21.170.170","article-title":"Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients; Results of 263 CD20+ patients studied prospectively in GMALL study 07\/2003","volume":"116","author":"Hoelzer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.10.006_bib43","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2014.10.006_bib44","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","article-title":"Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study","volume":"26","author":"Raetz","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.10.006_bib45","first-page":"3906","article-title":"Weekly inotuzumab ozogamicin (InO) in adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia (ALL)","volume":"122","author":"DeAngelo","year":"2013","journal-title":"Blood (ASH Annual Meeting)"},{"key":"10.1016\/j.beha.2014.10.006_bib46","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2014.10.006_bib47","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1172\/JCI61203","article-title":"Molecular genetics of B-precursor acute lymphoblastic leukemia","volume":"122","author":"Mullighan","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beha.2014.10.006_bib48","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.1073\/pnas.0800408105","article-title":"Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: unexpected similarities with pediatric disease","volume":"105","author":"Paulsson","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2014.10.006_bib49","doi-asserted-by":"crossref","first-page":"6912","DOI":"10.1182\/blood-2011-02-334359","article-title":"DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis","volume":"117","author":"Nguyen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.10.006_bib50","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","article-title":"Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor","volume":"20","author":"Daigle","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2014.10.006_bib51","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1172\/JCI61269","article-title":"The molecular basis of T cell acute lymphoblastic leukemia","volume":"122","author":"Van Vlierberghe","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beha.2014.10.006_bib52","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","article-title":"Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, hispanic\/latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia","volume":"115","author":"Harvey","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2014.10.006_bib53","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1158\/1078-0432.CCR-10-1203","article-title":"New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice","volume":"17","author":"Mullighan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2014.10.006_bib54","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2011.40.3907","article-title":"IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia","volume":"30","author":"Moorman","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2014.10.006_bib55","first-page":"743","article-title":"A\u00a0BCR-ABL1-like gene expression profile confers a poor prognosis in patients with high-risk acute lymphoblastic leukemia (HR-ALL): a report from Children's Oncology Group (COG) AALL0232","volume":"118","author":"Loh","year":"2011","journal-title":"Blood (ASH Annual Meeting)"},{"key":"10.1016\/j.beha.2014.10.006_bib56","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3324\/haematol.2010.026997","article-title":"The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia","volume":"96","author":"Saunders","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2014.10.006_bib57","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI31095","article-title":"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia","volume":"117","author":"Neviani","year":"2007","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beha.2014.10.006_bib58","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1158\/1078-0432.CCR-07-4839","article-title":"Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers","volume":"14","author":"Jeong","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2014.10.006_bib59","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/leu.2008.318","article-title":"Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia","volume":"23","author":"Deenik","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2014.10.006_bib60","first-page":"494","article-title":"PEG-asparaginase intensification in adult acute lymphoblastic leukemia (ALL): significant improvement of outcome with moderate increase of liver toxicity in the German Multicenter Study Group for Adult ALL (GMALL) Study 07\/2003","volume":"116","author":"Goekbuget","year":"2010","journal-title":"Blood (ASH Annual Meeting)"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692614000723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692614000723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T20:21:15Z","timestamp":1598386875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692614000723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":60,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S1521692614000723"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2014.10.006","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Will novel agents for ALL finally change the natural history?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2014.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}